Cancer Immunotherapy Collaborative Learning With Latha Shivakumar, PhD, CHCP

​ In the constantly evolving field of cancer immunotherapy, it is crucial that community practitioners keep abreast of the latest advances. In this interview with i3 Health, Latha Shivakumar, PhD, CHCP, discusses her poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting concerning the initiative she led at the Association of Community Cancer Centers (ACCC): collaborative learning workshops focused on best practices for immunotherapy in the community setting. What...
Continue reading

Knowledge Gaps Surrounding CRPC Risk Assessment, Treatment

Over the past few years, the treatment options for castration-resistant prostate cancer (CRPC) have increased to include novel hormone therapies, second-generation taxanes, immunotherapy, and bone-targeted and bone metastasis-targeted agents. Due to an absence of large prospective trials, clinical decision making needs to be based on many different factors, including optimal treatment sequences and combinations, patient health status (eg, asymptomatic or symptomatic), rate of disease progression...
Continue reading

Surveys Reveal Oncology Nurses’ CNE Preferences

​ At the Oncology Nursing Society (ONS) 44 th Annual Congress in Anaheim, California, in April 2019, i3 Health surveyed oncology nurses regarding their educational needs on a variety of topics, including immune checkpoint inhibitors, cyclin dependent kinase (CDK)4/6 inhibitors, chimeric antigen receptor (CAR) T-cell therapy, poly(ADP)-ribose polymerase (PARP) inhibitors, and biosimilars. Regardless of the survey topic, all respondents were asked about their practice role, practice setting, and p...
Continue reading

Survey of Oncology Nurses Reveals Knowledge Gaps Surrounding Immune Checkpoint Inhibitors

Immune checkpoint inhibition is a form of immunotherapy that blocks checkpoint proteins on immune cells, boosting the body's immune response against cancer cells. Checkpoint inhibitors such as pembrolizumab (Keytruda ® , Merck), nivolumab (Opdivo ® , Bristol-Myers Squibb), atezolizumab (Tecentriq ® , Genentech), durvalumab (Imfinzi ® , AstraZeneca), cemiplimab (Libtayo ® , Regeneron Pharmaceuticals, Inc.), ipilimumab (Yervoy ® , Bristol-Myers Squibb), and avelumab (Bavencio ® , EMD Serono and Pf...
Continue reading

Oncology Nurses’ Educational Needs: CDK4/6 Inhibitors

​ Cyclin dependent kinase (CDK)4/6 inhibitors have produced tremendous advances in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer through their targeting of hormone signals that stimulate the proliferation of cancer cells. Three CDK4/6 inhibitors have been FDA approved for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer: palbociclib (Ibrance®, Pfizer Inc.), ribociclib (Kisqali®, Nova...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.